Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors

Lung Cancer. 2012 Oct;78(1):121-4. doi: 10.1016/j.lungcan.2012.07.003. Epub 2012 Jul 25.

Abstract

A 34-year-old Japanese woman presented with left supraclavicular lymph node swelling. Computed tomography scans revealed a mass on the left lower lobe, pulmonary nodules, and pleural effusion. A lymph node biopsy revealed large-cell carcinoma with an epidermal growth factor receptor (EGFR) deletion mutation, L747-T751 in exon 19. Although malignant pleural effusions carried the same EGFR mutation, progressive pleural effusions after treatment with chemotherapy, gefitinib, and erlotinib did not show any EGFR mutation. A cell line established from the pleural effusion 3 days before the patient expired also did not harbor the EGFR mutation. Histological sections of the lymph node of the patient were similar to those of the xenograft tumor of the cell line. There may be genetic heterogeneity in EGFR mutant tumors.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Large Cell / diagnosis
  • Carcinoma, Large Cell / drug therapy
  • Carcinoma, Large Cell / genetics*
  • ErbB Receptors / genetics*
  • Exons
  • Female
  • Humans
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Mutation*
  • Neoplasm Staging
  • Protein Kinase Inhibitors / therapeutic use
  • Tomography, X-Ray Computed

Substances

  • Protein Kinase Inhibitors
  • ErbB Receptors